Feverfew Drug Interactions: Antiplatelet Effects, Warfarin, and NSAIDs
Feverfew is used primarily for migraine prevention — a use that puts it in the hands of people who often take other medications for the same condition, including NSAIDs, triptans, and in some cases anticoagulants. The active compound, parthenolide, has effects on platelets and on inflammatory signaling pathways that overlap with several common drug classes. Understanding these overlaps matters most for people who combine feverfew with medications that already suppress clotting or affect the same biochemical targets.
Parthenolide and platelet inhibition
Parthenolide is a sesquiterpene lactone that inhibits platelet aggregation by suppressing collagen-induced platelet activation and interfering with thromboxane A2 production. It also inhibits serotonin release from platelets — platelets store and release serotonin, which promotes further platelet aggregation and vasoconstriction. Blocking this serotonin release pathway reduces platelet activation via a mechanism distinct from most other antiplatelet agents.
These effects are additive with anticoagulants and antiplatelet medications. Warfarin reduces clot formation through the coagulation cascade (specifically by reducing vitamin K-dependent clotting factors); aspirin blocks thromboxane A2 synthesis via cyclooxygenase-1; clopidogrel blocks the P2Y12 ADP receptor. Feverfew's parthenolide adds platelet inhibition via the collagen-activation and serotonin pathways, which are distinct enough that the combination is genuinely additive rather than redundant. NCCIH notes that feverfew may interact with blood-thinning medications.
People taking warfarin alongside feverfew for migraine should be aware that INR measurements do not capture antiplatelet effects — warfarin's therapeutic monitoring measures coagulation cascade function, not platelet aggregation. Additional antiplatelet activity from feverfew would not show up as an elevated INR even if it is contributing to overall bleeding risk. This is the same limitation discussed for fish oil, garlic, and ginkgo: INR control is a necessary but not sufficient measure of bleeding risk when antiplatelet supplements are in use.
Interactions with NSAIDs and the "rebound" consideration
Feverfew combined with NSAIDs creates a different kind of concern. NSAIDs inhibit cyclooxygenase enzymes, which are the same pathway feverfew's parthenolide affects through prostaglandin synthesis modulation. This combination does not necessarily produce a dangerous pharmacological interaction, but long-term feverfew use followed by abrupt discontinuation is associated with a "post-feverfew syndrome" — a rebound phenomenon including increased headache frequency, joint pain, and anxiety — which is thought to reflect re-sensitization of the inflammatory and platelet pathways that feverfew suppressed. This is not technically a drug interaction but is a relevant clinical consideration for anyone using feverfew as a regular preventive supplement.
The evidence base for feverfew's drug interactions is primarily mechanistic and based on NCCIH's documented interaction list. Controlled pharmacokinetic studies are limited. The antiplatelet concern is the most clinically important, and it applies most directly to people on anticoagulant or antiplatelet therapy who add feverfew without disclosing it to their prescriber.